Why the study?
Is rivoroxaban effective and safe for thromboembolism prevention in patients with type I atrial flutter compared to patients with atrial fibrillation?
Is rivoroxaban effective and safe for thromboembolism prevention in patients with type I atrial flutter compared to patients with atrial fibrillation?
Answers are grounded in this paper and cite their sources.
Rivoroxaban appears effective and safe for thromboembolism prevention in patients with type I atrial flutter, with outcomes comparable to those seen in atrial fibrillation.
Aim. To assess effectiveness, safety and adherence to treatment of patients with type I atrial flutter who were previously excluded from the clinical trials evaluating the potential benefits of rivoroxaban for thromboembolism prevention. Methods. 27 medical records of patients with type I atrial flutter were retrospectively reviewed and assigned to the study group. The control group consisted of 100 patients with atrial fibrillation. Both groups received rivoroxaban. All patients underwent thromboembolism risk assessment with the CHA2DS2-VACs score, bleeding risk assessment with HAS-BLED score. Data were collected by telephone. Results. No thromboembolic events were registered in the atrial flutter group, whereas one case of ischemic stroke was in the atrial fibrillation group. There were no major bleedings in both groups. Four patients with atrial flutter and 2 patients with atrial fibrillation had hemorrhages. Patients’ adherence to rivoroxaban was 75–80%. Conclusion. Rivoroxaban therapy was found to be effective and safe in patients with type I atrial flutter including those who underwent cardioversion. High adherence to rivoroxaban therapy was demonstrated.
No takes yet. Share an insight, caveat, or question.
Федосеенко et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: